## Oncology Drug Targets Exploiting Targeted Protein Degradation (TPD)

A multinational pharmaceutical company is seeking **first-in-class novel/established drug targets for Targeted Protein Degradation (TPD), especially proteolysis-targeting chimeras (PROTACs) in oncology**. Priority cancers of interest are **biliary tract cancer, pancreatic cancer, non-small cell lung cancer (PD-L1 negative), prostate cancer (castration-resistant), urothelial cancer, acute myeloid leukaemia**. Other cancers such as breast cancer (triple-negative), ovarian cancer (platinum-resistant), soft tissue sarcoma and diffuse large B-cell lymphoma are also of interest.

Approaches of Interest

- Novel drug targets: no association has been reported for the cancer type.
- Established drug targets: clear association has been reported for the cancer type, but PROTACs have not been reported for the targets.
- For either target class, PROTAC approach needs to be feasible. The target should be ligandable.
- For either target class, PROTAC approach needs to be justifiable. Cellular efficacy should be shown by genetic/chemogenetic approaches such as CRISPR, RNAi, or dTAG etc. If inhibitors are available, comparison is necessary.

Developmental Stages of Interest:

- Opportunities at basic research phase to late preclinical research phase are within scope, provided the targets are validated in one of the above cancers of interest with patient-derived cells.
- Research related to novel, validated, unpublished targets is of high interest. It is not necessary that PROTAC has been found for the target.

Submission Information:

Submission of **one page, 200-300 word summaries of existing research and technologies** is encouraged, along with any optional supplementary information e.g., relevant publications and patents. **Our client is also open to receiving proposals for novel research, using this** application form . In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration:

Our client is open to a range of collaboration scenarios, with the most appropriate path determined by the needs of the opportunity. Licensing of assets is preferred, however research collaborations may be considered, with funding in the region of $300K/year (including overhead cost) available for high quality proposals.

Opportunities sought

- Technologies
- Academics and expertise
- Centres of excellence
- Research projects
- Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **20th February 2023 - 11:59 pm GMT**

Have any questions?
Contact our team at discover@in-part.co.uk